RESUMEN
Dermatitis herpetiformis has been investigated in the past; however, only a limited number of studies have reported its incidence based on validated nationwide population-based registries. To address this gap, the aims of this study are to estimate the incidence of dermatitis herpetiformis in Sweden and to validate the National Patient Register (NPR) for diagnosis of dermatitis herpetiformis. A population-based open cohort study was conducted, including all patients diagnosed with dermatitis herpetiformis (International Classification of Diseases 10th revision; ICD-10 code L13.0) in Sweden from 2005 to 2018 (n = 1,724), identified from the NPR. The diagnosis of dermatitis herpetiformis in the NPR was validated using medical records, histopathological and immunopathological data, yielding a positive predictive value (PPV) of 62.5%. The mean annual incidence of dermatitis herpetiformis was 0.93/100,000 (95% confidence interval 0.79-1.08), female to male ratio 1:1, and mean age at diagnosis 60.9 years. In conclusion, this large nationwide cohort study showed a low validity for diagnosis of dermatitis herpetiformis in the NPR, and the adjusted incidence rate of dermatitis herpetiformis in Sweden was estimated to be 0.93/100,000, which is lower than that in previous Swedish studies.
Asunto(s)
Dermatitis Herpetiforme , Humanos , Masculino , Femenino , Persona de Mediana Edad , Estudios de Cohortes , Suecia/epidemiología , Incidencia , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Estudios RetrospectivosRESUMEN
INTRODUCTION: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. Increased cardiovascular morbidity has been reported in coeliac disease, but in DH only little is known about this. In this cohort study with a long-term follow-up, the risk for vascular diseases in patients with dermatitis herpetiformis (DH) and coeliac disease was assessed. METHODS: The study consisted of 368 DH and 1072 coeliac disease patients with biopsy-proven diagnosis performed between 1966 and 2000. For each DH and coeliac disease patient three matched reference individuals were obtained from the population register. Data regarding all outpatient and inpatient treatment periods between 1970 and 2015 were reviewed for diagnostic codes of vascular diseases from the Care Register for Health Care. Cox proportional hazard model was used to assess the risks for the diseases studied and the HRs were adjusted for diabetes mellitus (aHR). RESULTS: The median follow-up time of DH and coeliac disease patients was 46 years. The risk for cardiovascular diseases did not differ between DH patients and their references (aHR 1.16, 95% CI 0.91-1.47), but among coeliac disease patients, the risk was increased (aHR 1.36, 95% CI 1.16-1.59). The risk for cerebrovascular diseases was found to be decreased in DH patients when compared with references (aHR 0.68, 95% CI 0.47-0.99) and increased in coeliac disease patients (aHR 1.33, 95% CI 1.07-1.66). The risk for venous thrombosis was increased in coeliac disease patients (aHR 1.62, 95% CI 1.22-2.16) but not in DH. CONCLUSIONS: The risk for vascular complications appears to differ between DH and coeliac disease. In DH the risk for cerebrovascular diseases seems to be decreased, while in coeliac disease an elevated risk for cerebrovascular and cardiovascular diseases was observed. These differing vascular risk profiles between the two manifestations of the same disease merit further investigation.
An increased risk for cardiovascular diseases was observed among patients with coeliac disease, but not among patients with dermatitis herpetiformis, a cutaneous manifestation of coeliac disease.The risk for cerebrovascular diseases was shown to be decreased in dermatitis herpetiformis patients, but conversely, an increased risk for cerebrovascular diseases was identified in coeliac disease patients.Coeliac disease, but not dermatitis herpetiformis, was shown to be associated with increased risk for venous thrombosis.
Asunto(s)
Enfermedades Cardiovasculares , Enfermedad Celíaca , Dermatitis Herpetiforme , Enfermedades Vasculares , Humanos , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/epidemiología , Enfermedad Celíaca/diagnóstico , Dermatitis Herpetiforme/complicaciones , Dermatitis Herpetiforme/epidemiología , Dermatitis Herpetiforme/diagnóstico , Estudios de Cohortes , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/complicaciones , Enfermedades Vasculares/complicacionesRESUMEN
BACKGROUND: An increased risk of kidney disease in patients with celiac disease has been reported, but the association has remained obscure. Only few studies have investigated the association between renal comorbidities and dermatitis herpetiformis, a cutaneous manifestation of celiac disease. OBJECTIVES: We investigated whether patients with different phenotypes of celiac disease are at higher risk of kidney diseases than age- and sex-matched references. METHODS: The diagnoses of glomerulonephritis, diabetic nephropathy, interstitial nephritis, and end-stage renal disease obtained from the National Hospital Discharge Register between 1970 and 2015 were identified in celiac disease (Marsh III, n = 1072) and dermatitis herpetiformis (n = 368) patients diagnosed at Tampere University Hospital catchment region and in 4296 reference subjects. Using the Cox proportional hazards model, we compared the risk of kidney diseases between patients and references. The study protocol was approved by the Regional Ethics Committee of Tampere University Hospital (R16090). As the study was register based, no consent from patients was required. RESULTS: Even after adjusting for type 1 diabetes, celiac disease was associated with an elevated risk of kidney disease (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.12-3.03), glomerulonephritis (HR 3.37, 95% CI 1.64-6.95), and IgA nephropathy (IgAN) (HR 18.98, 95% CI 2.29-157.63). No similarly elevated risk was found among dermatitis herpetiformis patients (HR 1.50, 95% CI 0.63-3.55; HR 2.21, 95% CI 0.77-6.38; and HR 5.87, 95% CI 0.53-64.79, respectively). CONCLUSION: Celiac disease patients were at increased risk of kidney diseases, notably IgAN. The risk was dependent on the celiac disease phenotype and was not seen in patients with dermatitis herpetiformis. Awareness of possible renal manifestations is recommended when treating celiac disease patients.
Asunto(s)
Enfermedad Celíaca , Dermatitis Herpetiforme , Glomerulonefritis por IGA , Glomerulonefritis , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/epidemiología , Dermatitis Herpetiforme/complicaciones , Dermatitis Herpetiforme/epidemiología , Glomerulonefritis/complicaciones , Glomerulonefritis/epidemiología , Glomerulonefritis por IGA/complicaciones , Glomerulonefritis por IGA/epidemiología , Humanos , Fenotipo , Estudios RetrospectivosRESUMEN
Dermatitis herpetiformis is a cutaneous manifestation of coeliac disease treated with a gluten-free diet. However, the itching and blistering rash alleviates slowly after gluten withdrawal and occasionally persists despite a long-term gluten-free diet. This study investigated the prevalence and factors associated with prolonged (i.e. >2 years) and ongoing skin symptoms in 237 patients with dermatitis herpetiformis. Data were gathered from medical records and via questionnaires. Among patients with dermatitis herpetiformis, 38% had prolonged symptoms after diagnosis, and 14% had ongoing skin symptoms at follow-up (median duration of gluten-free diet 24 years). A severe rash at diagnosis was associated with both prolonged and ongoing cutaneous symptoms. In addition, patients with dermatitis herpetiformis with ongoing skin symptoms at follow-up had been on the dietary treatment for a shorter time (median duration 16 vs 25 years) and were less often on a strict diet (53% vs 78%) compared with patients with dermatitis herpetiformis without ongoing skin symptoms.
Asunto(s)
Enfermedad Celíaca , Dermatitis Herpetiforme , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/epidemiología , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Dieta Sin Gluten , Glútenes/efectos adversos , Humanos , PrevalenciaRESUMEN
Dermatitis herpetiformis (DH), Duhring disease, is caused by gluten sensitivity and affects 11.2 to 75.3 per 100,000 people in the United States and Europe with an incidence of 0.4 to 3.5 per 100,000 people per year. DH is characterized by a symmetrical blistering rash on the extensor surfaces with severe pruritus. The diagnosis continues to be made primarily by pathognomonic findings on histopathology, especially direct immunofluorescence (DIF). Recently, anti-epidermal transglutaminase (TG3) antibodies have shown to be a primary diagnostic serology, while anti-tissue transglutaminase (TG2) and other autoantibodies may be used to support the diagnosis and for disease monitoring. Newly diagnosed patients with DH should be screened and assessed for associated diseases and complications. A gluten-free diet (GFD) and dapsone are still mainstays of treatment, but other medications may be necessary for recalcitrant cases. Well-controlled DH patients, managed by a dermatologist, a gastroenterologist, and a dietician, have an excellent prognosis. Our review comprehensively details the current diagnostic methods, as well as methods used to monitor its disease course. We also describe both the traditional and novel management options reported in the literature.
Asunto(s)
Enfermedad Celíaca , Dermatitis Herpetiforme , Autoanticuerpos , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/terapia , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/tratamiento farmacológico , Dermatitis Herpetiforme/epidemiología , Dieta Sin Gluten , Humanos , Inmunoglobulina A , PronósticoRESUMEN
Dermatitis herpetiformis is a cutaneous manifestation of coeliac disease. Anaemia is a common finding in patients with untreated coeliac disease, but little is known about the occurrence of anaemia in those with dermatitis herpetiformis. This study investigated the prevalence of anaemia and factors associated with anaemia in 250 patients with dermatitis herpetiformis, at diagnosis and one year after diagnosis. As controls, 139 patients with coeliac disease were included. Patient records were reviewed to gather baseline clinical, histological, and laboratory data. Follow-up data for patients with dermatitis herpetiformis were collected from patient records and via questionnaires or at follow-up visits. The prevalence of anaemia was 12% in patients with dermatitis herpetiformis and 17% in patients with coeliac disease at diagnosis (p = 0.257). Anaemia in patients with dermatitis herpetiformis was not associated with the severity of skin symptoms or small bowel damage. The prevalence of anaemia at a 1-year follow-up had increased to 19%, but it was associated mainly with dapsone treatment.
Asunto(s)
Anemia , Enfermedad Celíaca , Dermatitis Herpetiforme , Anemia/diagnóstico , Anemia/epidemiología , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/epidemiología , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Estudios de Seguimiento , Humanos , PrevalenciaRESUMEN
Dermatitis herpetiformis (DH), presenting with an intense itch and blistering symmetrical rash, typically on the elbows, knees, and buttocks, is a cutaneous manifestation of celiac disease. Though overt gastrointestinal symptoms are rare, three-fourths of patients with DH have villous atrophy in the small bowel, and the rest have celiac-type inflammatory changes. DH affects mostly adults and slightly more males than females. The mean age at onset is about 50 years. DH diagnosis is confirmed by showing granular immunoglobulin A deposits in the papillary dermis. The DH autoantigen, transglutaminase 3, is deposited at the same site in tightly bound immune complexes. At present, the DH-to-celiac disease prevalence is 1:8. The incidence of DH is decreasing, whereas that of celiac disease is increasing, probably because of improved diagnostics. In DH, the treatment of choice for all patients is a gluten-free diet (GFD) in which uncontaminated oats are allowed. At onset, most patients need additional dapsone to rapidly control the rash and itching. Dapsone can be stopped after a mean of 2 years, and a strict lifelong GFD alone is required. Dietary adherence offers an excellent long-term prognosis for patients with DH, with a normal quality of life and all-cause mortality.
Asunto(s)
Enfermedad Celíaca/terapia , Dapsona/uso terapéutico , Dermatitis Herpetiforme/terapia , Dieta Sin Gluten , Adulto , Factores de Edad , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/epidemiología , Enfermedad Celíaca/inmunología , Terapia Combinada/métodos , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Dermatitis Herpetiforme/inmunología , Dermis/efectos de los fármacos , Dermis/inmunología , Dermis/patología , Femenino , Humanos , Inmunoglobulina A/análisis , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Intestino Delgado/efectos de los fármacos , Intestino Delgado/inmunología , Intestino Delgado/patología , Masculino , Cooperación del Paciente , Prevalencia , Pronóstico , Calidad de Vida , Factores de Riesgo , Factores Sexuales , Resultado del TratamientoRESUMEN
Vesicobullous lesions of skin may occur in different forms of dermatosis, which include various inflammatory, infective, autoimmune, drug induced as well as genetic conditions. Autoimmune bullous lesions, may be fatal if not treated with appropriate agents. Bearing in mind, the morbidity of these diseases, it is important to establish a firm diagnosis. A diagnostic skin biopsy with immunofluorescence is frequently used to confirm a clinical diagnosis, especially where it is not apparent clinically. There are many centres in India where immunofluorescence is not available and the diagnosis in these lesions is based on clinical and histopathological features only. Here in this study, we studied 53 skin punch biopsies with clinical suspicion of vesicobullous lesions followed by histopathological examination was carried out over a period of 2 years in a Medical College in Gujarat. Lesions were categorised based on the location of the blister. 1) Suprabasal 2) subcorneal 3) and subepidermal. Further subtyping was done based on additional histopathological features and clinical correlation. All the patients responded appropriately to the treatment and the results correlated well with the immunofluorescence done in a few cases. This study lays emphasis upon the histopathology and clinical features keeping in consideration of the lack of ancillary techniques in many centres especially in the developing world.
Asunto(s)
Vesícula/diagnóstico , Piel/patología , Adulto , Anciano , Biopsia , Vesícula/epidemiología , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Pénfigo/diagnóstico , Pénfigo/epidemiología , Enfermedades Cutáneas Vesiculoampollosas/diagnóstico , Enfermedades Cutáneas Vesiculoampollosas/epidemiologíaAsunto(s)
Enfermedad Celíaca/complicaciones , Dermatitis Herpetiforme/epidemiología , Dieta Sin Gluten , Adulto , Enfermedad Celíaca/dietoterapia , Enfermedad Celíaca/inmunología , Consejo , Dermatitis Herpetiforme/dietoterapia , Dermatitis Herpetiforme/inmunología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Encuestas y Cuestionarios/estadística & datos numéricos , Adulto JovenRESUMEN
Dermatitis herpetiformis (DH) is an autoimmune skin disease that causes itchy, blistering rash, typically on the elbows, knees and buttocks. DH and coeliac disease share the same genetic background, gluten-dependent enteropathy and antibody response against tissue transglutaminase. DH is currently considered a cutaneous manifestation of coeliac disease, and the prevailing hypothesis is that DH develops as a late manifestation of subclinical coeliac disease. The incidence of DH is decreasing contemporarily with the increasing incidence of coeliac disease. The IgA immune response in DH skin is directed against epidermal transglutaminase, while the autoantigen in the gut is tissue transglutaminase. Granular IgA deposition in the papillary dermis is pathognomonic for DH, and is a finding used to confirm the diagnosis. The treatment of choice for DH is a life-long gluten-free diet, which resolves the rash and enteropathy, increases quality of life, and offers a good long-term prognosis.
Asunto(s)
Enfermedades Autoinmunes/epidemiología , Enfermedad Celíaca/epidemiología , Enfermedad Celíaca/inmunología , Dapsona/administración & dosificación , Dermatitis Herpetiforme/epidemiología , Dermatitis Herpetiforme/terapia , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/fisiopatología , Enfermedades Autoinmunes/terapia , Enfermedad Celíaca/fisiopatología , Enfermedad Celíaca/terapia , Terapia Combinada , Comorbilidad , Dermatitis Herpetiforme/inmunología , Dieta Sin Gluten , Femenino , Humanos , Incidencia , Masculino , Pronóstico , Medición de Riesgo , Transglutaminasas/metabolismo , Resultado del TratamientoRESUMEN
Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease (CD), which causes an itching and blistering rash, typically on the elbows, knees and buttocks. DH and CD share a similar genetic background, small bowel mucosal alterations, and an autoimmune response against tissue transglutaminase in the serum and small bowel. DH is typically diagnosed during adulthood, and it is slightly more common among males than females. The incidence of DH seems to be decreasing, in contrast to the detected four-fold increase in the incidence of CD. In addition to typical clinical picture, diagnosis of DH relies on the demonstration by direct immunofluorescence of pathognomonic granular IgA deposits in the papillary dermis. Circulating tissue transglutaminase antibodies support the diagnosis, but their absence does not exclude DH. Obtainment of small bowel mucosal biopsies is not necessary when DH is diagnosed, but if performed, the majority of patients are found to have villous atrophy, and even those with normal villous architecture evince CD-type inflammation. The treatment of choice in DH is a strict, life-long adherence to a gluten-free diet (GFD). In addition to alleviating the symptoms of DH and healing the small bowel mucosal damage, a GFD increases the quality of life for patients, and decreases the risk for lymphoma in DH. Further, the mortality rate of patients with DH treated with a GFD seems to be lower than that of the general population. However, as changing to a GFD has a rather slow effect on the DH rash, patients with severe skin symptoms should additionally be treated with dapsone medication. This review article is based on a presentation given at the British Society for Medical Dermatology blistering skin diseases meeting 2019.
Asunto(s)
Enfermedad Celíaca/dietoterapia , Dermatitis Herpetiforme/dietoterapia , Dermatitis Herpetiforme/diagnóstico , Dieta Sin Gluten , Enfermedad Celíaca/complicaciones , Dermatitis Herpetiforme/epidemiología , Dermatitis Herpetiforme/etiología , Humanos , PronósticoRESUMEN
Bullous pemphigoid (BP) and dermatitis herpetiformis (DH) are autoimmune bullous skin diseases. DH has been described to evolve into BP and the two diseases can have overlapping clinical appearances and diagnostic findings, but the association between DH and BP has not previously been studied in a large population. To evaluate DH and celiac disease as risk factors for BP, we conducted a retrospective case-control study of patients with BP and matched controls with basal cell carcinoma diagnosed in Finland between 1997 and 2013. A total of 3,397 patients with BP and 12,941 controls were included in the study. Forty-one (1.2%) BP patients and 7 (0.1%) controls had preceding DH. Diagnosed DH increased the risk of BP 22-fold (odds ratio = 22.30; 95% confidence interval = 9.99-49.70) and celiac disease 2-fold (odds ratio = 2.54; 95% confidence interval = 1.64-3.92) compared to controls. Eighteen (43.9%) of the patients who had DH and subsequent BP had bought dapsone during the 2 years prior to their BP diagnosis. Mean time between diagnosed DH and BP was 3 years. We conclude that diagnosis of DH is associated with a striking increase in the risk for BP.
Asunto(s)
Enfermedad Celíaca/epidemiología , Dermatitis Herpetiforme/epidemiología , Penfigoide Ampolloso/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Dapsona/uso terapéutico , Dermatitis Herpetiforme/tratamiento farmacológico , Femenino , Finlandia/epidemiología , Humanos , Leprostáticos/uso terapéutico , Masculino , Persona de Mediana Edad , Penfigoide Ampolloso/tratamiento farmacológico , Estudios Retrospectivos , RiesgoRESUMEN
The skin is the largest organ of the body, at the boundary with the outside environment. Primarily, it provides a physical and chemical barrier against external insults, but it can act also as immune organ because it contains a whole host of immune-competent cells of both the innate and the adaptive immune systems, which cooperate in eliminating invading pathogens following tissue injury. On the other hand, improper skin immune responses lead to autoimmune skin diseases (AISD), such as pemphigus, bullous pemphigoid, vitiligo, and alopecia. Although the interplay among genetic, epigenetic, and environmental factors has been shown to play a major role in AISD etiology and progression, the molecular mechanisms underlying disease development are far from being fully elucidated. In this context, epidemiological studies aimed at defining the association of different AISD with other autoimmune pathologies revealed possible shared molecular mechanism(s) responsible for disease progression. In particular, over the last decades, a number of reports have highlighted a significant association between thyroid diseases (TD), mainly autoimmune ones (AITD), and AISD. Here, we will recapitulate the epidemiology, clinical manifestations, and pathogenesis of the main AISD, and we will summarize the epidemiological evidence showing the associations with TD as well as possible molecular mechanism(s) underlying TD and AISD pathological manifestations.
Asunto(s)
Alopecia Areata , Enfermedades Autoinmunes , Dermatitis Herpetiforme , Psoriasis , Enfermedades Cutáneas Vesiculoampollosas , Enfermedades de la Tiroides , Vitíligo , Alopecia Areata/epidemiología , Alopecia Areata/etiología , Alopecia Areata/inmunología , Enfermedades Autoinmunes/epidemiología , Enfermedades Autoinmunes/etiología , Enfermedades Autoinmunes/inmunología , Dermatitis Herpetiforme/epidemiología , Dermatitis Herpetiforme/etiología , Dermatitis Herpetiforme/inmunología , Humanos , Psoriasis/epidemiología , Psoriasis/etiología , Psoriasis/inmunología , Enfermedades Cutáneas Vesiculoampollosas/epidemiología , Enfermedades Cutáneas Vesiculoampollosas/etiología , Enfermedades Cutáneas Vesiculoampollosas/inmunología , Enfermedades de la Tiroides/epidemiología , Enfermedades de la Tiroides/etiología , Enfermedades de la Tiroides/inmunología , Vitíligo/epidemiología , Vitíligo/etiología , Vitíligo/inmunologíaRESUMEN
Dermatitis herpetiformis (DH) is an extra-intestinal manifestation of coeliac disease. The highest currently reported prevalence of DH is in Finland, but knowledge of diagnostic delay is limited. This study investigated the duration of rash prior to diagnosis in 446 patients with DH, analysing the results in 3 periods of 15 years. The diagnosis was considered delayed when the duration of rash before diagnosis was 2 years or longer. Factors associated with delayed diagnosis were analysed. Within the 45 years, the median duration of rash before diagnosis decreased significantly, from 12.0 to 8.0 months (p?=?0.002) and the occurrence of a delayed diagnosis decreased from 47% to 25% (p?=?0.002). Female sex, the presence of villous atrophy, and a diagnosis of DH before the year 2000 were significantly associated with delayed diagnosis. In conclusion, the present study showed that one-quarter of patients currently have a diagnostic delay of 2 years or more, which is far from ideal.
Asunto(s)
Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/epidemiología , Diagnóstico Tardío , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Piel/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Atrofia , Biopsia , Enfermedad Celíaca/patología , Niño , Preescolar , Dermatitis Herpetiforme/patología , Femenino , Finlandia/epidemiología , Humanos , Intestino Delgado/patología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Prevalencia , Estudios Prospectivos , Factores de Riesgo , Factores Sexuales , Factores de Tiempo , Adulto JovenRESUMEN
BACKGROUND: Little is known about the epidemiology of pediatric autoimmune blistering disorders (PAIBD). OBJECTIVE: We sought to determine the inpatient burden and comorbidities of PAIBD. METHODS: We analyzed data from the Nationwide Inpatient Sample from 2002 to 2012, which contained a representative 20% sample of all US hospitalizations. RESULTS: The most common PAIBD with a primary admission was pemphigus (8.0 per million), whereas the most common secondary diagnosis of PAIBD was dermatitis herpetiformis (DH; 9.6 per million). Bullous pemphigoid (BP) was inversely associated with being female and having government or no insurance but positively associated with Black and Hispanic race/ethnicity and more chronic conditions. Pemphigus was associated with being female, Hispanic, having government or no insurance, and having a higher number of chronic conditions. DH was inversely associated with non-White race but positively associated with having government insurance and more chronic conditions. BP was associated with dialysis, hypertension, and diabetes. Pemphigus was associated with osteoarthritis, renal failure, hypothyroidism, and weight loss. DH was associated with herpes simplex virus infection, rheumatoid arthritis, and fungal, viral, and other skin infections. CONCLUSION: PAIBD are associated with a considerable inpatient burden and comorbid health conditions.
Asunto(s)
Costo de Enfermedad , Dermatitis Herpetiforme/economía , Dermatitis Herpetiforme/epidemiología , Hospitalización/economía , Penfigoide Ampolloso/economía , Penfigoide Ampolloso/epidemiología , Pénfigo/economía , Pénfigo/epidemiología , Adolescente , Niño , Preescolar , Estudios de Cohortes , Comorbilidad , Femenino , Humanos , Lactante , Recién Nacido , Tiempo de Internación , Masculino , Factores Sexuales , Estados Unidos/epidemiologíaRESUMEN
GOALS: We analyzed from our prospectively collected series of patients with dermatitis herpetiformis (DH) whether small-bowel histologic findings are changing and how serum tissue transglutaminase (TG2) IgA antibodies correlate to mucosal damage. BACKGROUND: DH is an extraintestinal manifestation of celiac disease presenting with itchy blistering rash and pathognomonic IgA deposits in the skin. Prominent gastrointestinal symptoms are rare, and small-bowel findings range from severe villous atrophy (SVA) and partial villous atrophy (PVA) to normal mucosa with inflammatory changes. METHODS: The cohort included 393 patients (214 male and 179 female) with DH having small-bowel biopsies performed at Tampere University Hospital since 1970. The small-bowel findings were calculated in the three 15-year periods, and in the last period they were correlated with serum IgA class TG2 antibody levels measured by enzyme-linked immunosorbent assay. RESULTS: The prevalence of SVA decreased significantly (P=0.032), from 42% in the first study period to 29% in the last study period. A concomitant increase was seen in PVA, from 33% to 41%, and normal villous architecture, from 25% to 30%. The patients with SVA (P<0.001) and PVA (P=0.046) had significantly higher TG2 antibody levels than those with normal villous architecture. CONCLUSIONS: This long-term study in patients with DH disclosed a significant decrease in the occurrence of SVA. Serum IgA TG2 antibody levels correlated to damage in the small bowel. The trend toward milder small-bowel histology in DH suggests that a similar pattern could occur in the pool of undiagnosed celiac disease from which DH develops.
Asunto(s)
Dermatitis Herpetiforme/epidemiología , Mucosa Intestinal/patología , Intestino Delgado/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Atrofia , Autoanticuerpos/sangre , Estudios de Cohortes , Dermatitis Herpetiforme/sangre , Dermatitis Herpetiforme/patología , Dieta Sin Gluten , Femenino , Finlandia/epidemiología , Proteínas de Unión al GTP/inmunología , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Prevalencia , Proteína Glutamina Gamma Glutamiltransferasa 2 , Índice de Severidad de la Enfermedad , Transglutaminasas/inmunología , Adulto JovenAsunto(s)
Crioglobulinemia/epidemiología , Crioglobulinas/metabolismo , Dermatitis Herpetiforme/etiología , Fibrinógenos Anormales/metabolismo , Adulto , Crioglobulinemia/sangre , Crioglobulinemia/complicaciones , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/epidemiología , Humanos , Hungría/epidemiología , Masculino , Persona de Mediana Edad , PrevalenciaRESUMEN
OBJECTIVE: The presentation of celiac disease (CD) has changed over the past decades. We aimed to describe the incidence of CD and its complications at diagnosis in a historical cohort in a well-defined population in Denmark. METHODS: We included all patients aged 15+ years, who lived in Aarhus County, Denmark, and who were diagnosed with CD between January 2008 and August 2013. Data regarding gastrointestinal symptoms, anthropometrics, biochemistry, and bone mineral density were retrieved from patient records. RESULTS: A total of 93 patients with a valid CD diagnosis were identified, corresponding to an incidence rate of 6.4 per 100,000 person-years. At diagnosis, diarrhea and weight loss occurred in 54% and 47% patients, respectively. In total, 30% had anemia; 40%, iron deficiency; 20%, folate deficiency; and 17%, vitamin B12 deficiency. Vitamin D deficiency was present in 34%. In 28%, bone mineral density was determined during the first year after diagnosis. Of these, 54% had osteopenia and 12% osteoporosis. After introduction of a gluten-free diet, 28% had normalized transglutaminase antibody levels after 6 months, and 56% did after 12 months. Diabetes mellitus type 1 was present in 7%; dermatitis herpetiformis, in 3%; and thyroid dysfunction, in 5%. CONCLUSIONS: Only half of newly diagnosed CD patients presented with classic gastrointestinal symptoms. Anemia and vitamin deficiencies were common. Bone mineral density was determined in less than a third of the patients, and osteoporosis occurred in 12% of these. Serologic markers of CD normalized in approximately half of patients during the first year after the diagnosis.
Asunto(s)
Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/epidemiología , Evaluación de Síntomas , Adolescente , Adulto , Anciano , Anemia/etiología , Autoanticuerpos/sangre , Densidad Ósea , Enfermedad Celíaca/diagnóstico , Comorbilidad , Dinamarca/epidemiología , Dermatitis Herpetiforme/epidemiología , Diabetes Mellitus Tipo 1/epidemiología , Diarrea/etiología , Femenino , Ácido Fólico , Deficiencia de Ácido Fólico/etiología , Proteínas de Unión al GTP/inmunología , Humanos , Incidencia , Deficiencias de Hierro , Masculino , Persona de Mediana Edad , Osteoporosis/etiología , Proteína Glutamina Gamma Glutamiltransferasa 2 , Estudios Retrospectivos , Enfermedades de la Tiroides/epidemiología , Transglutaminasas/inmunología , Deficiencia de Vitamina B 12/etiología , Deficiencia de Vitamina D/etiología , Pérdida de PesoRESUMEN
BACKGROUND: Dermatitis herpetiformis (DH) is a cutaneous manifestation of celiac disease. Both conditions are treated with a restrictive life-long gluten-free diet (GFD). Treated celiac disease patients have been shown to have more severe gastrointestinal symptoms and inferior quality of life compared with healthy controls, but evidence regarding quality of life in DH is lacking. OBJECTIVE: The aim was to evaluate whether long-term GFD-treated DH patients suffer from persistent gastrointestinal symptoms and if they experience a drawdown in quality of life. METHODS: Gastrointestinal symptoms and quality of life were assessed in 78 long-term GFD-treated DH patients using the validated Gastrointestinal Symptom Rating Scale, Psychological General Well-Being and Short Form 36 Health Survey questionnaires. The findings were compared with 110 healthy controls, population-based reference values and 371 treated celiac disease controls. RESULTS: The median age of the DH patients at the time of the study was 57 years, and 51 % were male. Significant differences in gastrointestinal symptoms or quality of life were not detected when treated DH patients were compared with healthy controls, but treated DH patients had less severe gastrointestinal symptoms and increased quality of life compared with celiac disease controls. Female DH patients had more severe gastrointestinal symptoms and reduced vitality compared with male DH patients. The presence of skin symptoms and the adherence to or duration of GFD did not have any influence on gastrointestinal symptoms or quality of life. CONCLUSION: We conclude that long-term GFD-treated DH patients do not suffer from the burden of dietary treatment and have a quality of life comparable to that of controls.
Asunto(s)
Enfermedad Celíaca/dietoterapia , Enfermedad Celíaca/epidemiología , Dermatitis Herpetiforme/dietoterapia , Dermatitis Herpetiforme/epidemiología , Dieta Sin Gluten , Calidad de Vida , Adolescente , Adulto , Factores de Edad , Anciano , Enfermedad Celíaca/fisiopatología , Comorbilidad , Estudios Transversales , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/psicología , Diagnóstico Precoz , Femenino , Finlandia , Humanos , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Valores de Referencia , Medición de Riesgo , Índice de Severidad de la Enfermedad , Factores Sexuales , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Pemphigus herpetiformis (PH) is a rare subtype of pemphigus that presents challenges in diagnosis. OBJECTIVE: To review the presentation, diagnosis, and management of PH. METHODS: We reviewed the charts of all patients diagnosed and treated for PH in an immunobullous referral center between September 2007 and June 2013. RESULTS: Eight patients were identified with a diagnosis of PH. All presented initially with pruritus. Clinical disease was manifest as either urticated erythematous plaques or a vesiculobullous eruption. Histological evaluation demonstrated eosinophilic spongiosis in all patients with acantholysis in half of cases (n = 4/8). Peripheral eosinophilia was noted in three of eight (37.5%) patients. In all cases, direct immunofluorescence showed intercellular deposition of immunoglobulin G in the epidermis. All patients required high-dose corticosteroid initially. All patients treated with dapsone or sulfasalazine (n = 4) achieved at least partial control. Other effective treatments included intravenous immunoglobulin (n = 2), azathioprine (n = 2), and leflunomide (n = 1). Rituximab was ineffective in two patients. CONCLUSION: The clinical and histological features of PH develop over time and with treatment, making distinction between pemphigus subtypes challenging and delay in diagnosis common. Diagnosis of PH requires a high index of suspicion and is made on clinical grounds (urticated erythema) in the context of compatible histology and immunofluorescence findings. Treatment may be challenging, although efficacy of sulfonamide derivatives appears to offer a therapeutic effect.